Objective: To assess the differences and similarities in efficacy, safety, and metabolic effects
of oral contraceptives (OCs) containing the new progestins desogestrel, gestodene, and …

New generation oral contraceptives containing desogestrel or gestodene, and possibly also
norgestimate, are more or less similar with respect to contraceptive efficacy, cycle control …

The aim of using new synthetic progestogens (gestodene and norgestimate) in oral
hormonal contraceptives is to find a combination that has a more beneficial effect on …

This review details the characteristic features of three new progestogens which soon will be
available in low-combination oral contraceptive agents in the United States. Available data …

Oral contraceptives (OCs) were initially approved for unrestricted use in 1960 in the United
States and have been used and studied extensively for 30 years. The initial formulations …

Objective: To review and compare the newer progestins desogestrel, norgestimate, and
gestodene with regard to chemistry, pharmacokinetics, efficacy, and tolerability. Data …

The contraceptive efficacy, cycle control, safety, and subject acceptance of the new
contraceptive (OC) preparations containing gestodene (GTD) plus ethinyl estradiol (EE) are …

Epidemiologic studies indicate that the risk of complications with oral contraceptive use is
related to the steroid content and potency of the various formulations. This paper …

Three new 19-nortestosterone progestogens, which are chemically related to levonorgestrel,
are now clinically available in combination oral contraceptives in Europe. Desogestrel and …

Low-dose combined oral contraceptives (COC) containing new progestogens recently have
been introduced in the United Kingdom. Are these preparations more effective and safer …